About Astheneia Bio

Our Mission

Our Technologies

Our Pipeline

At Astheneia Bio, our mission is to develop first in class and first line therapies using different platforms. Astheneia Bio's dual-immunotherapy platform will revolutionize the access, speed, efficiency, and cost by which cancer patients are treated for their disease.

3D model CLTX-CAR neutrophil carrying drug loaded nanoparticles (blue)

Our Pipeline

Our Technologies

Our Pipeline

Glioblastoma Multiforme

Prostate

Other Solid

Liquid

Alzheimers Disease

live cell imaging of a CAR-neutrophil

Our Technologies

Visit the 'Our Science' page for more technologies coming to Astheneia.

Astheneia Bio's neutrophil technology is different than other cell therapies. Astheneia's technology produces genetically modified neutrophils to target and destroy solid tumors. CAR-neutrophils can carry and deliver nanodrugs to the local tumor site.

live cell imaging

Neu=CLTX-CAR-Neutrophil

Tu=GBM Tumor

10um scale

Our TEam

Founder, CEO, Board

FOUNDER, SR. ADVISOR, BOARD

Founder, CEO, Board

Tamara Jovonovich, PhD

20-years in pharmaceutical development

Founder, COO, Board

FOUNDER, SR. ADVISOR, BOARD

Founder, CEO, Board

CEO of ARTA Therapeutics infectious disease company;

30-years in pharmaceutical development

FOUNDER, SR. ADVISOR, BOARD

CEO of Ceoptis Therapeutics, publicly traded immunotherapy company

CSO

Scientific advisory board

FOUNDER, SR. ADVISOR, BOARD

Professor Xiaoping Bao

Inventor of the CAR-neutrophil technology and patent applications holder; Assistant Professor, Davidson School of Chemical Engineering, Purdue University.

Scientific advisory board

Angela Richardson, MD

Assistant Professor of Neurological Surgery and Department of Biochemistry and Molecular Biology, Indiana University